Quell Therapeutics, a London-based biotech developing immune cell therapies to target transplant rejection and autoimmune and inflammatory diseases.

Less than a month after Thermo Fisher unveiled a $1.7 billion deal to swallow Brammer Bio — a company that does contract viral vector manufacturing for cell ...